As sporadic patients represent the majority of PD cases, genomic data might also play an important role in extending the application of these therapies to sporadic patients with GBA/LRRK2-associated mutations, should these mutations be identified in this cohort. The gene discussed is LRRK2; the disease is Parkinson disease.